America Needs a Pharmaceutical Strategy—And Washington Is Beginning to Build One

For decades, prescription drugs in America were treated primarily as a healthcare issue. The Food and Drug Administration determined whether medicines were safe and effective, insurers and government programs worried about what they cost, and pharmaceutical companies largely decided where to invest, manufacture and conduct research. Trade and national security policy occupied a different conversation. 

Those lines are disappearing. Pharmaceuticals are increasingly being treated the way Washington now treats semiconductors, energy and critical minerals: not simply as commercial products, but as strategic assets with implications for national security, economic competitiveness and American resilience. 

The Trump Administration has accelerated that transformation and, importantly, has correctly identified several structural problems that have been building for decades. Americans pay substantially more for many innovative medicines than patients in other developed countries. Too much pharmaceutical manufacturing and too many critical inputs have migrated overseas. Foreign governments have benefited from American-financed pharmaceutical innovation while using their purchasing power to suppress prices at home. At the same time, increasingly concentrated global supply chains have created vulnerabilities in products essential to American health and national security. 

The Administration is now attacking these problems simultaneously through Most-Favored Nation pricing, pharmaceutical tariffs, incentives for domestic manufacturing, efforts to reduce foreign supply-chain dependence and reforms intended to accelerate drug development. These initiatives are often discussed separately, but they are increasingly interconnected. 

Together, they represent the beginnings of something America has lacked for too long: a comprehensive pharmaceutical strategy. 

From Healthcare Policy to Economic Statecraft 

The scale of the change is becoming difficult to ignore. The Administration's Most-Favored Nation initiative seeks to bring the prices Americans pay for innovative medicines closer to those paid in other developed countries. The underlying principle is straightforward: the world's largest and most valuable pharmaceutical market should not routinely require Americans to pay dramatically more for the same medicines sold elsewhere.

At the same time, the Administration is using trade policy to confront America's dependence on foreign pharmaceutical production. Its pharmaceutical tariff framework explicitly links national security, domestic manufacturing and drug pricing. Companies that enter into Most-Favored Nation pricing agreements and approved onshoring agreements can receive preferential tariff treatment, directly connecting what Americans pay for medicine with decisions about where those medicines are produced. 

That represents a significant change in the relationship between Washington and the pharmaceutical industry. The emerging message to manufacturers is that access to the world's largest pharmaceutical market increasingly comes with broader expectations: provide American patients with fairer prices, invest more in the United States, expand domestic manufacturing and research, and reduce strategic dependence on vulnerable foreign supply chains. 

Industry is responding. Pharmaceutical manufacturers have announced hundreds of billions of dollars in U.S. manufacturing and research investments as companies reassess the economics of where medicines sold to Americans should be developed and produced. For years, policymakers talked about reshoring critical industries. The pharmaceutical sector is now beginning to move capital. 

The opportunity is to turn that momentum into a durable strategy. 

Start With the American Patient 

The ultimate objective cannot simply be building more pharmaceutical factories, nor should it be protecting the existing pharmaceutical industry. The objective should be a pharmaceutical system that works better for the American people. That means pursuing affordable medicines, secure supply, vigorous competition and continued innovation while also addressing an issue that has been ignored for too long: fair international burden-sharing. 

For decades, many wealthy countries have used government purchasing power and price controls to obtain innovative medicines at prices well below those paid in the United States. Pharmaceutical manufacturers accepted those arrangements in significant part because returns from the American market helped sustain the economics of global drug development. The result has been an increasingly difficult arrangement to defend: American patients effectively pay more while other wealthy nations benefit from medicines whose development is disproportionately supported by the U.S. market. 

President Trump's Most-Favored-Nation initiative directly challenges that model, and rightly so. But the best long-term outcome is not simply lower American prices if that ultimately results in less global investment in pharmaceutical innovation. It is a rebalancing in which Americans pay less while other wealthy countries shoulder a greater and fairer share of the cost of developing the medicines their citizens also consume.

That is not an argument against pharmaceutical innovation. It is an argument for sharing its cost more fairly. 

But what a manufacturer charges is only part of what determines what an American ultimately pays. The increasingly complex network of pharmacy benefit managers, rebates, formularies and other intermediaries can obscure the actual economics of a prescription and prevent savings negotiated elsewhere in the system from fully reaching patients at the pharmacy counter. A patient-centered pharmaceutical strategy must therefore address not only manufacturer pricing but also how medicines are priced, reimbursed and delivered throughout the system. Greater transparency and competition should ensure that savings ultimately reach the person purchasing the medicine. 

Innovation and Monopoly Are Not the Same Thing 

There is another distinction policymakers should preserve as this strategy develops. Supporting pharmaceutical innovation does not require protecting every element of the existing pharmaceutical business model. 

Developing a genuinely novel medicine capable of treating cancer, Alzheimer's disease, diabetes or a rare genetic disorder deserves substantial economic reward. Drug development requires enormous investment, frequently over many years, with no guarantee that a promising molecule will ever become an approved medicine. America should remain the best country in the world in which to take those risks. 

But rewarding innovation and encouraging competition are not contradictory objectives. When legitimate patent protection ends, competition should begin. Generic and biosimilar manufacturers should be able to enter markets efficiently, FDA approvals should remain rigorous but timely, and unnecessary regulatory barriers to competition should be examined. Policymakers should also distinguish genuine scientific innovation from strategies primarily intended to extend commercial exclusivity without producing comparable benefits for patients. 

Innovation creates tomorrow's medicines. Competition makes yesterday's breakthroughs broadly affordable. 

A healthy pharmaceutical ecosystem needs both, and American policy should protect both sides of that equation. 

The Cheapest Drug Is Not Necessarily the Lowest-Cost Drug 

Price cannot be the only consideration. America has already learned that lesson in other strategic industries. Energy markets, for example, spent years rewarding the lowest-cost unit of electricity without always fully valuing reliability, dispatchability, fuel security and resilience. Only when systems became stressed did the economic value of those attributes become obvious.

Pharmaceuticals face an analogous problem. Consider two identical critical medicines. One costs somewhat less but depends entirely upon a highly concentrated foreign supply chain. The other costs somewhat more but can be reliably produced domestically or obtained from several trusted suppliers. The first medicine has the lower purchase price, but that does not necessarily make it the lower-cost option for the United States. A hospital cannot treat a patient with a drug it cannot obtain. 

COVID-19 exposed vulnerabilities in global medical supply chains, and subsequent geopolitical competition has reinforced the lesson. Efficiency remains essential to an affordable healthcare system, but efficiency without sufficient resilience can create strategic vulnerability. The Trump Administration is therefore right to focus on restoring strategically important pharmaceutical manufacturing capacity to the United States. 

The more difficult question is determining which capacity America actually needs.

“Available to America” Matters More Than “Made in America” 

America does not need to manufacture every medicine it consumes. Trying to do so would be enormously expensive, economically inefficient and ultimately unnecessary. The strategic objective should instead be ensuring that critical medicines are always available to Americans. 

For some products, that will require domestic manufacturing. Certain antibiotics, antivirals, emergency medicines, medical countermeasures, critical active pharmaceutical ingredients and products essential to national security or hospital operations may warrant assured American production capacity. For other important medicines, diversified production among trusted allies may provide sufficient resilience. Many ordinary commercial pharmaceuticals can and should continue to be supplied through competitive global markets.

This distinction matters as the Administration expands its use of pharmaceutical tariffs. Tariffs are already changing investment calculations, and the substantial manufacturing commitments being made by pharmaceutical companies demonstrate that altering the economics of imported medicines can influence corporate behavior. The next step is ensuring that the manufacturing brought home strengthens America's long-term pharmaceutical security while ultimately benefiting American patients. 

The objective should not simply be counting factories. It should be reducing vulnerabilities. Then There Is China 

The challenge becomes considerably more complicated when China enters the equation. For years, America's pharmaceutical discussion surrounding China concentrated largely on manufacturing, active pharmaceutical ingredients and supply-chain dependence. That conversation is changing as China increasingly becomes a source of pharmaceutical innovation itself.

Chinese biotechnology companies are developing promising molecules and licensing them to Western pharmaceutical companies. What was once principally a manufacturing relationship is becoming increasingly intertwined with global research and development. That creates a strategic contradiction: Washington appropriately wants American companies to reduce dangerous dependencies on China, while pharmaceutical companies have strong incentives to search the world for promising science—and increasingly some of that science is emerging from China. 

The strategic question is therefore no longer simply whether America should manufacture more medicines domestically. It is whether the United States can reduce dangerous dependence on China while ensuring that American companies and patients continue to benefit from legitimate scientific advances wherever they occur. How Washington manages that distinction will become increasingly important to both pharmaceutical policy and the broader U.S.-China economic relationship. 

The Economics of Innovation Are Changing 

There is another reason America needs a strategy rather than a collection of individual policies: the economics of pharmaceutical innovation themselves may be approaching a significant transition.

Many of the pharmaceutical industry's largest products will lose patent protection over the coming years. Companies must replace those revenues with new medicines, increasing pressure to acquire biotechnology companies, license promising compounds and search globally for new sources of innovation. At the same time, artificial intelligence, computational modeling, new clinical-trial approaches and advanced manufacturing may begin reducing the time and cost required to develop medicines. 

The FDA is already moving in this direction. Recent initiatives are intended to modernize clinical development and allow regulators to make better use of emerging technologies and data. The important question about artificial intelligence may therefore not be whether an AI system independently discovers the next blockbuster drug, but whether these technologies can materially reduce the time, cost and failure rate associated with moving promising science from the laboratory to the patient. 

If they can, some of today's assumptions about the relationship between pharmaceutical prices and the cost of innovation could change substantially. America should want that transformation to happen here. 

Five Tests for an American Pharmaceutical Strategy 

The Trump Administration has put many of the necessary pieces on the table. The opportunity now is to make sure they work together. Every significant pharmaceutical policy should therefore be measured against five basic tests:

• Does it lower costs for American patients? 

• Does it encourage genuine competition? 

• Does it strengthen America's access to medicines it cannot afford to lose? • Does it preserve—and ideally strengthen—the incentives for genuine pharmaceutical innovation? 

• Does it require other wealthy countries to bear a fairer share of the cost of that innovation? 

No single policy will maximize all five. Maximum supply-chain independence may increase costs. Excessive price compression could reduce investment incentives. Unrestricted dependence on global markets can create vulnerabilities, while excessive intellectual-property protection can suppress competition. These are real tradeoffs, and strategy requires recognizing and managing them rather than pretending they do not exist. 

That strategy should also preserve what has made the United States the world's leading pharmaceutical innovator. The goal should not be to replace America's market-driven pharmaceutical system with government planning. It should be to use competition, transparency, regulatory reform and targeted government action where necessary to make that system work better for American patients while strengthening the country's strategic position. 

An Opportunity America Should Not Waste 

The United States begins this transition from a position of extraordinary strength. We have world-class universities and research institutions, deep capital markets, leading biotechnology and pharmaceutical companies, sophisticated healthcare infrastructure, extraordinary scientific talent and the world's most important pharmaceutical market. Now capital is beginning to move back toward American pharmaceutical manufacturing as well. 

The Trump Administration has correctly reframed pharmaceuticals as more than a healthcare cost issue. Drug pricing, manufacturing, supply-chain security, trade, scientific innovation and national security are interconnected. The task now is to transform that recognition into a durable strategy that survives individual policies, companies and political cycles. 

That means confronting high American drug prices without undermining genuine innovation; ensuring savings actually reach patients rather than being absorbed by intermediaries; rewarding scientific breakthroughs without tolerating artificial barriers to competition; rebuilding strategically important manufacturing capacity without pretending every pill must be produced domestically; and reducing dangerous foreign dependencies without isolating American scientists and companies from global innovation. It also means insisting that America's wealthy allies share more fairly in the cost of developing the medicines from which their citizens benefit. 

We have encountered versions of these challenges elsewhere. Semiconductors taught us that extraordinary technological capability can coexist with dangerous manufacturing concentration. 

Energy has demonstrated that low prices and reliability are not always synonymous. Critical minerals have shown that possessing advanced technology means little if another country controls essential inputs. Pharmaceuticals contain elements of all three. 

The United States now has an opportunity to apply those lessons before the next crisis forces us to. The Administration has started that process, and the objective should remain clear: make medicines more affordable for Americans, ensure those savings reach patients, make critical supply chains more secure, keep markets competitive and ensure that the next generation of medical breakthroughs continues to be developed in the United States. 

That is more than healthcare policy. It is economic statecraft.

Rick Westerdale has more than 30 years of experience across the federal government as well as in the global energy industry. As a Vice President at Connector, Inc., a boutique government relations and political affairs firm based in Washington, D.C., Rick advises clients on strategy, investment, and policy across healthcare, hydrocarbons, LNG, hydrogen, nuclear, and the broader energy transition.